Quantification of clonal circulating plasma cells in relapsed multiple myeloma

Wilson Gonsalves, William G. Morice, S Vincent Rajkumar, Vinay Gupta, Michael M. Timm, Angela Dispenzieri, Francis K. Buadi, Martha Lacy, Preet P. Singh, Prashant Kapoor, Morie Gertz, Shaji K Kumar

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Summary: The presence of clonal circulating plasma cells (cPCs) remains a marker of high-risk disease in newly diagnosed multiple myeloma (MM) patients. However, its prognostic utility in MM patients with previously treated disease is unknown. We studied 647 consecutive patients with previously treated MM seen at the Mayo Clinic, Rochester who had their peripheral blood evaluated for cPCs by multi-parameter flow cytometry. Of these patients, 145 had actively relapsing disease while the remaining 502 had disease that was in a plateau and included 68 patients in complete remission (CR) and 434 patients with stable disease. Patients with actively relapsing disease were more likely to have clonal cPCs than those in a plateau (P < 0·001). None of the patients in CR had any clonal cPCs detected. Among patients whose disease was in a plateau, the presence of clonal cPCs predicted for a worse median survival (22 months vs. not reached; P = 0·004). Among actively relapsing patients, the presence of ≥100 cPCs predicted for a worse survival after flow cytometry analysis (12 months vs. 33 months; P < 0·001). Future studies are needed to determine the role of these findings in developing a risk-adapted treatment approach in MM patients with actively relapsing disease.

Original languageEnglish (US)
Pages (from-to)500-505
Number of pages6
JournalBritish Journal of Haematology
Volume167
Issue number4
DOIs
StatePublished - Nov 1 2014

Fingerprint

Plasma Cells
Multiple Myeloma
Flow Cytometry
Survival

Keywords

  • Circulating plasma cells
  • Multiple myeloma
  • Survival

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

Quantification of clonal circulating plasma cells in relapsed multiple myeloma. / Gonsalves, Wilson; Morice, William G.; Rajkumar, S Vincent; Gupta, Vinay; Timm, Michael M.; Dispenzieri, Angela; Buadi, Francis K.; Lacy, Martha; Singh, Preet P.; Kapoor, Prashant; Gertz, Morie; Kumar, Shaji K.

In: British Journal of Haematology, Vol. 167, No. 4, 01.11.2014, p. 500-505.

Research output: Contribution to journalArticle

@article{0913dc9c64d44f3a8b785842c7aae0f3,
title = "Quantification of clonal circulating plasma cells in relapsed multiple myeloma",
abstract = "Summary: The presence of clonal circulating plasma cells (cPCs) remains a marker of high-risk disease in newly diagnosed multiple myeloma (MM) patients. However, its prognostic utility in MM patients with previously treated disease is unknown. We studied 647 consecutive patients with previously treated MM seen at the Mayo Clinic, Rochester who had their peripheral blood evaluated for cPCs by multi-parameter flow cytometry. Of these patients, 145 had actively relapsing disease while the remaining 502 had disease that was in a plateau and included 68 patients in complete remission (CR) and 434 patients with stable disease. Patients with actively relapsing disease were more likely to have clonal cPCs than those in a plateau (P < 0·001). None of the patients in CR had any clonal cPCs detected. Among patients whose disease was in a plateau, the presence of clonal cPCs predicted for a worse median survival (22 months vs. not reached; P = 0·004). Among actively relapsing patients, the presence of ≥100 cPCs predicted for a worse survival after flow cytometry analysis (12 months vs. 33 months; P < 0·001). Future studies are needed to determine the role of these findings in developing a risk-adapted treatment approach in MM patients with actively relapsing disease.",
keywords = "Circulating plasma cells, Multiple myeloma, Survival",
author = "Wilson Gonsalves and Morice, {William G.} and Rajkumar, {S Vincent} and Vinay Gupta and Timm, {Michael M.} and Angela Dispenzieri and Buadi, {Francis K.} and Martha Lacy and Singh, {Preet P.} and Prashant Kapoor and Morie Gertz and Kumar, {Shaji K}",
year = "2014",
month = "11",
day = "1",
doi = "10.1111/bjh.13067",
language = "English (US)",
volume = "167",
pages = "500--505",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Quantification of clonal circulating plasma cells in relapsed multiple myeloma

AU - Gonsalves, Wilson

AU - Morice, William G.

AU - Rajkumar, S Vincent

AU - Gupta, Vinay

AU - Timm, Michael M.

AU - Dispenzieri, Angela

AU - Buadi, Francis K.

AU - Lacy, Martha

AU - Singh, Preet P.

AU - Kapoor, Prashant

AU - Gertz, Morie

AU - Kumar, Shaji K

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Summary: The presence of clonal circulating plasma cells (cPCs) remains a marker of high-risk disease in newly diagnosed multiple myeloma (MM) patients. However, its prognostic utility in MM patients with previously treated disease is unknown. We studied 647 consecutive patients with previously treated MM seen at the Mayo Clinic, Rochester who had their peripheral blood evaluated for cPCs by multi-parameter flow cytometry. Of these patients, 145 had actively relapsing disease while the remaining 502 had disease that was in a plateau and included 68 patients in complete remission (CR) and 434 patients with stable disease. Patients with actively relapsing disease were more likely to have clonal cPCs than those in a plateau (P < 0·001). None of the patients in CR had any clonal cPCs detected. Among patients whose disease was in a plateau, the presence of clonal cPCs predicted for a worse median survival (22 months vs. not reached; P = 0·004). Among actively relapsing patients, the presence of ≥100 cPCs predicted for a worse survival after flow cytometry analysis (12 months vs. 33 months; P < 0·001). Future studies are needed to determine the role of these findings in developing a risk-adapted treatment approach in MM patients with actively relapsing disease.

AB - Summary: The presence of clonal circulating plasma cells (cPCs) remains a marker of high-risk disease in newly diagnosed multiple myeloma (MM) patients. However, its prognostic utility in MM patients with previously treated disease is unknown. We studied 647 consecutive patients with previously treated MM seen at the Mayo Clinic, Rochester who had their peripheral blood evaluated for cPCs by multi-parameter flow cytometry. Of these patients, 145 had actively relapsing disease while the remaining 502 had disease that was in a plateau and included 68 patients in complete remission (CR) and 434 patients with stable disease. Patients with actively relapsing disease were more likely to have clonal cPCs than those in a plateau (P < 0·001). None of the patients in CR had any clonal cPCs detected. Among patients whose disease was in a plateau, the presence of clonal cPCs predicted for a worse median survival (22 months vs. not reached; P = 0·004). Among actively relapsing patients, the presence of ≥100 cPCs predicted for a worse survival after flow cytometry analysis (12 months vs. 33 months; P < 0·001). Future studies are needed to determine the role of these findings in developing a risk-adapted treatment approach in MM patients with actively relapsing disease.

KW - Circulating plasma cells

KW - Multiple myeloma

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84916197779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84916197779&partnerID=8YFLogxK

U2 - 10.1111/bjh.13067

DO - 10.1111/bjh.13067

M3 - Article

C2 - 25113422

AN - SCOPUS:84916197779

VL - 167

SP - 500

EP - 505

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 4

ER -